Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Prioriteiten afgestemd Afschaffing van voorschrift voor personen met dementie en hun verzorger

21 oktober 2026 bijgewerkt door: Aanand Dinkar Naik, The University of Texas Health Science Center, Houston

The purpose of this study is to compare patient priorities care (PPC) and usual care (UC) patients to identify differences in post-encounter medication changes, treatment burden (TBQ), and shared decision making in Older Patient Assessment of Chronic Illness Care (OPACIC), to understand PPC participant's sense-making and communication approaches related to deprescribing decisions in relation to the identified health priorities and to identify and categorize adverse drug withdrawal events (ADWEs)

Studie Overzicht

Toestand

Voltooid

Conditie

Studietype

Ingrijpend

Inschrijving (Werkelijk)

98

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

    • Texas
      • Houston, Texas, Verenigde Staten, 77030
        • The University of Texas Health Science Center at Houston

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

55 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Dementia listed as an active problem in the medical record, including Alzheimer's disease, vascular dementia, frontotemporal dementia, Parkinson's dementia, Lewy body disease.
  • The functional assessment staging tool (FAST) score of 5 or lower (This will be established by the patient's clinician).
  • 2 or more additional chronic conditions
  • Takes 5 or more regular medications and
  • A caregiver present during visits. Caregivers may include family members or unrelated caregivers and will be identified through chart review and confirmed by clinician, patient, and surrogate decision maker if necessary. Identified caregivers must be involved in decisions and care of People living with dementia (PLWD) and routinely attend clinic visits with patient

Exclusion Criteria:

  • FAST score of 6 or more (This will be established by the patient's clinician).
  • Significant hearing, vision, or advanced cognitive impairment that limits ability to participate in PPC encounters,
  • Caregiver is unwilling or able to participate in visits, or
  • Deemed ineligible by their Primary care physician (PCP)

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Ondersteunende zorg
  • Toewijzing: Niet-gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Enkel

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Actieve vergelijker: Gebruikelijke zorg

Participants will have a geriatric clinic visit with a geriatrician that acts as their primary care provider (PCP) , in which the dyads will be encouraged by an unblinded study coordinator to ask about reducing medication burden.

Experimenteel: PPC

Participants will have an encounter with a facilitator who will identify priorities (outcome goals and care preferences) from the dyads and transmits them in the electronic health records (EHR), and a follow-up encounter with their usual geriatric care provider to decide upon changes in their care that align with the identified priorities.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Total Number of Medication Changes
Tijdsspanne: Baseline, 3 month

Total Number of medication changes that happened between baseline and three month follow up among Dementia Participants.

Baseline, 3 month
Type of Medication Changes
Tijdsspanne: Baseline, 3 month

Medication changes corresponding to the type of changes among Dementia Participants: added or increased, discontinued or decreased, avoided.

Baseline, 3 month
Number of Participants by Change in Patient Report Treatment Burden as Assessed by the Treatment Burden Questionnaire (TBQ)
Tijdsspanne: Baseline, 3 month

The questionnaire consists of 15 items, each scored on a scale from 0 (not a problem) to 10 (a very big problem), yielding a total score range of 0 to 150, with higher scores indicating greater treatment burden.

TBQ total scores were assessed at baseline and at 3 months. Change in treatment burden was calculated by subtracting the baseline total TBQ score from the 3-month TBQ score (3 month minus baseline).

Participants were categorized based on change in score as follows:

  • reduced burden (change score < 0)
  • no change in burden (change score = 0)
  • increased burden (change score > 0)
Baseline, 3 month
Number of Participants by Likelihood of Adverse Drug Reactions (ADRs) as Assessed by the Naranjo Scale
Tijdsspanne: 3 months

Naranjo scale is a questionnaire used to assess the likelihood that an adverse event is related to a drug. Total scores range from -4 to +13.

Adverse drug reactions were categorized based on total score as follows:

  • Definite (≥ 9): Reaction followed a reasonable temporal sequence after drug exposure, matched a recognized drug response, improved after withdrawal, and recurred upon re-exposure.
  • Probable (5 to 8): Reaction followed drug exposure, matched a recognized drug response, improved after withdrawal, and was not reasonably explained by the patient's clinical condition.
  • Possible (1 to 4): Reaction followed drug exposure and may fit a recognized drug response but could also be explained by the underlying disease or other factors.
  • Doubtful (≤ 0): The reaction was due to factors other than a drug.
  • No Adverse Reaction: Participants who did not experience any adverse reactions. The Naranjo Scale was not administered because there was no suspected reaction to evaluate.
3 months
Number of Participants by Adverse Drug Withdrawal Events (ADWEs) as Assessed by the Naranjo Scale
Tijdsspanne: 3 months

The Naranjo Scale assesses the likelihood that an adverse event is related to a drug withdrawal. Total scores range from -4 to +13.

Adverse drug withdrawal events (ADWEs) were categorized as follows:

  • Definite (≥ 9): Withdrawal reaction followed drug discontinuation, matched a recognized withdrawal syndrome, improved with treatment or re-exposure, and recurred after subsequent discontinuation
  • Probable (5 to 8): Withdrawal reaction followed drug discontinuation, matched a recognized withdrawal syndrome, improved with management or re-exposure, and could not be explained by the patient's condition
  • Possible (1 to 4): Withdrawal reaction followed drug discontinuation and may fit a recognized withdrawal syndrome but could also be explained by an underlying disease or other factors.
  • Doubtful (≤ 0): Withdrawal reaction likely due to factors other than drug discontinuation
  • No Withdrawal Reaction: No suspected adverse drug withdrawal event. The Naranjo Scale was not administered
3 months

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change in Patient Perceived Chronic Disease Care as Assessed by the Older Patient Assessment of Chronic Illness Care (OPACIC) Score
Tijdsspanne: Baseline, 3 months

The Older Patient Assessment of Chronic Illness Care (OPACIC) score ranges from 10 to 50, with higher scores indicating better perceived chronic disease care. The change in score is reported as [(OPACIC score at 3 months) - (OPACIC score at baseline)]--a positive value indicates improvement in perceived chronic disease care over time.

Baseline, 3 months

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: Aanand D Naik, MD, The University of Texas Health Science Center, Houston

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

6 juli 2023

Primaire voltooiing (Werkelijk)

30 juni 2025

Studie voltooiing (Werkelijk)

30 juni 2025

Studieregistratiedata

Eerst ingediend

24 juli 2023

Eerst ingediend dat voldeed aan de QC-criteria

24 juli 2023

Eerst geplaatst (Werkelijk)

1 augustus 2023

Updates van studierecords

Laatste update geplaatst (Werkelijk)

13 november 2026

Laatste update ingediend die voldeed aan QC-criteria

21 oktober 2026

Laatst geverifieerd

1 juni 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • HSC-SPH-22-0639
  • 5R24AG064025-05 (Subsidie/contract van de Amerikaanse NIH)

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren